摘要
目的通过比较各种扩血管药物的疗效及毒副作用,为急诊科治疗椎动脉型颈椎病时合理选用扩血管药物提供参考依据。方法选择发病时间在24h以内的椎动脉型颈椎病216例,随机分为四组,每组54例,分别以具代表性的四种扩血管药物复方丹参、前列地尔(PGE1)、654-2、长春西汀予以治疗,观察并相互比较各组疗效及毒副作用。结果在缓解椎动脉型颈椎病时,在96h内四种药物的疗效无显著性差异(P>0.05),但达显效所用时间则明显不同(P<0.05),从长到短依次为长春西汀、PGE1、654-2、复方丹参。结论综合考虑各药的疗效、不良反应及价格因素,四药各有优劣,从药理作用方面来说,长春西汀在治疗椎动脉型颈椎病时前景更好。
Objective To compare the efficacies of various vasodilator agents for the treatment of vertebral artery-type cervical spondylopathy.Methods 216 cases falling ill in 24 hours were divided randomly into four groups and the efficacies and side effects were compared with co-salcia miltiorrhiza injection（CSMI）,prostagland E1（PGE1）,anisodamine（654-2）and vinpocetine.Results In 96 hours,they could produce same effects,but they spent different time periods（P〈0.05）.The order of the time was vinpocetine PGE1 654-2 CSMI.Conclusion CSMI,PGE1,654-2 and vinpocetine have samilar efficacies in the treatment of vertebral artery-type cervical spondylopathy,but vinpocetine reachs excellent efficacy very quickly.
出处
《海南医学》
CAS
2010年第14期55-57,共3页
Hainan Medical Journal
关键词
复方丹参
前列地尔
654-2
长春西汀
椎动脉型颈椎病
Co-salcia miltiorrhiza injection
Prostagland E1
Anisodamine
Vinpocetine
Vertebral artery-type cervical spondylopathy
